Ansbert Gadicke Sells 59,277 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

by · The Markets Daily

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ansbert Gadicke sold 59,277 shares of the business’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $0.89, for a total transaction of $52,756.53. Following the completion of the sale, the insider directly owned 4,924,566 shares in the company, valued at approximately $4,382,863.74. This represents a 1.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

  • On Thursday, December 4th, Ansbert Gadicke sold 83,230 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total transaction of $80,733.10.
  • On Wednesday, December 3rd, Ansbert Gadicke sold 57,225 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $49,785.75.
  • On Monday, December 1st, Ansbert Gadicke sold 60,917 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $57,261.98.
  • On Friday, November 28th, Ansbert Gadicke sold 20,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $20,074.23.
  • On Wednesday, November 26th, Ansbert Gadicke sold 60,733 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $59,518.34.
  • On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $39,130.36.
  • On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $87,025.96.
  • On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total value of $53,394.73.
  • On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $36,625.28.
  • On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $62,344.56.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL opened at $0.95 on Friday. The stock has a market capitalization of $46.20 million, a PE ratio of -0.59 and a beta of 0.74. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The firm has a fifty day simple moving average of $1.37 and a 200 day simple moving average of $1.33. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Bank of America cut their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. JMP Securities reduced their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Finally, Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.75.

Check Out Our Latest Report on HOWL

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $409,000. Citadel Advisors LLC acquired a new position in Werewolf Therapeutics in the 3rd quarter valued at $304,000. Vanguard Group Inc. increased its position in Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after buying an additional 109,796 shares during the period. Marshall Wace LLP bought a new position in Werewolf Therapeutics during the 2nd quarter worth $113,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Werewolf Therapeutics during the second quarter worth $92,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Read More